Zhang Yanbing, Zhang Xinge, Huang Chuiguo, Zhu Lei
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Biomedicines. 2025 Apr 13;13(4):956. doi: 10.3390/biomedicines13040956.
: Recently, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). Through analysis of the trends and disparities regarding cardiovascular disease (CVD) among individuals with MASLD, identifying the leading cause of death in this population is crucial. : We conducted a cross-sectional analysis of National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and NHANES 2017-2020 data. MASLD was identified by using clinical profiles and liver ultrasonography to exclude other liver diseases. We estimated the prevalence of CVD among individuals with MASLD and calculated the prevalence ratios for those with and without MASLD. : In 2017-2020, MASLD affected 31.2% or 61.9 million US adults, and 17.0% (95% confidence interval: 13.7-20.3%) of these individuals had CVD. The absolute CVD prevalence in individuals with MASLD doubled from that in the NHANES III cohort, which was 8.7% (6.4%, 10.9%). These increases were especially notable among older adults, non-Hispanic whites, and those with higher education and income. Individuals with MASLD had a higher prevalence of total CVD than those without MASLD, even after adjusting for socioeconomic and metabolic factors. These differences were more pronounced in younger age groups. : This study revealed a doubled 30-year trend in CVD prevalence among adults with MASLD in the US. Sociodemographic disparities emphasize the need for tailored screening, prevention, and policy measures to address gaps and promote cardiovascular health in this population.
最近，代谢功能障碍相关脂肪性肝病（MASLD）这一术语已取代非酒精性脂肪性肝病（NAFLD）。通过分析患有MASLD的个体中心血管疾病（CVD）的趋势和差异，确定该人群的主要死因至关重要。
我们对国家健康与营养检查调查（NHANES）III（1988 - 1994年）和NHANES 2017 - 2020年的数据进行了横断面分析。通过使用临床特征和肝脏超声检查来排除其他肝脏疾病，从而确定MASLD。我们估计了患有MASLD的个体中CVD的患病率，并计算了患有和未患有MASLD的个体的患病率比值。
在2017 - 2020年期间，MASLD影响了31.2%（即6190万）的美国成年人，其中17.0%（95%置信区间：13.7 - 20.3%）的个体患有CVD。患有MASLD的个体中CVD的绝对患病率是NHANES III队列中患病率（8.7%，6.4%，10.9%）的两倍。这些增加在老年人、非西班牙裔白人以及受教育程度和收入较高的人群中尤为明显。即使在调整了社会经济和代谢因素之后，患有MASLD的个体中总CVD的患病率仍高于未患有MASLD的个体。这些差异在较年轻的年龄组中更为明显。
这项研究揭示了美国患有MASLD的成年人中CVD患病率在30年里增长了一倍。社会人口统计学差异强调了需要采取针对性的筛查、预防和政策措施，以解决差距并促进该人群的心血管健康。
